Using cost-effectiveness thresholds to determine value for money in low-and middle-income country healthcare systems: Are current international norms fit for purpose? by Revill, Paul et al.
This is a repository copy of Using cost-effectiveness thresholds to determine value for 
money in low-and middle-income country healthcare systems: Are current international 
norms fit for purpose?.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/136186/
Version: Published Version
Monograph:
Revill, Paul orcid.org/0000-0001-8632-0600, Walker, Simon Mark 
orcid.org/0000-0002-5750-3691, Madan, Jason et al. (5 more authors) (2014) Using 
cost-effectiveness thresholds to determine value for money in low-and middle-income 
country healthcare systems: Are current international norms fit for purpose? Working 
Paper. CHE Research Paper . Centre for Health Economics, University of York , York, UK. 
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Using Cost-Effectiveness Thresholds to  
Determine Value for Money in Low- and  
Middle-Income Country Healthcare Systems: 
Are Current International Norms Fit for Purpose? 
 
 
 
 
 
 
 
CHE Research Paper 98 
  
  
 
 
 
 
 
 
 
 
Using cost-effectiveness thresholds to determine value for 
money in low- and middle-income country healthcare 
systems: Are current international norms fit for purpose?   
 
 
 
 
 
 
Paul Revill1A 
Simon Walker1A 
Jason Madan2 
Andrea Ciaranello3 
Takondwa Mwase4 
Diana M Gibb5 
Karl Claxton1 
Mark J Sculpher1 
 
 
AContributed equally  
 
 
 
1Centre for Health Economics, University of York, UK  
2Warwick Medical School, University of Warwick, UK 
3Massachusetts General Hospital, Massachusetts, USA 
4Abt Associates, Lilongwe, Malawi 
5Medical Research Council Clinical Trials Unit (MRC CTU), at University College 
London, UK 
 
 
 
 
 
May 2014 
  
Background to series 
CHE Discussion Papers (DPs) began publication in 1983 as a means of making current 
research material more widely available to health economists and other potential 
users. So as to speed up the dissemination process, papers were originally published 
by CHE and distributed by post to a worldwide readership.  
 
The CHE Research Paper series takes over that function and provides access to 
current research output via web-based publication, although hard copy will continue 
to be available (but subject to charge). 
 
Disclaimer 
Papers published in the CHE Research Paper (RP) series are intended as a 
contribution to current research. Work and ideas reported in RPs may not always 
represent the final position and as such may sometimes need to be treated as work 
in progress. The material and views expressed in RPs are solely those of the authors 
and should not be interpreted as representing the collective views of CHE research 
staff or their research funders. 
 
Further copies 
Copies of this paper are freely available to download from the CHE website 
www.york.ac.uk/che/publications/ Access to downloaded material is provided on 
the understanding that it is intended for personal use. Copies of downloaded papers 
may be distributed to third-parties subject to the proviso that the CHE publication 
source is properly acknowledged and that such distribution is not subject to any 
payment. 
 
Printed copies are available on request at a charge of £5.00 per copy. Please contact 
the CHE Publications Office, email che-pub@york.ac.uk, telephone 01904 321405 for 
further details. 
 
 
Centre for Health Economics 
Alcuin College 
University of York 
York, UK 
www.york.ac.uk/che 
 
 
 
 
 
 
 
 
© Paul Revill, Simon Walker, Jason Madan, Andrea Ciaranello, Takondwa Mwase, 
Diana M Gibb, Karl Claxton, Mark J Sculpher 
Using cost-effectiveness thresholds to determine value for money in low- and middle-income country healthcare systems i  
Abstract  
Healthcare systems in low- and middle-income countries face considerable population healthcare 
needs with markedly fewer resources than those in higher income countries.  The way in which 
available resources are allocated across competing priorities has a profound effect on how much 
health is generated overall, who receives healthcare interventions and who goes without.  
Judgements about whether interventions and programmes should be regarded as cost-effective and 
prioritised over others should be based on an assessment of the health benefits that will be lost 
because the resources required will not be available to implement other effective interventions and 
programmes that would benefit other patients in the same or different disease areas.  
Unfortunately, frequently adopted international norms, in particular the cost-effectiveness 
thresholds recommended by the World Health Organization (WHO), are not founded on this type of 
assessment.  Consequently current judgements about which interventions and programmes are 
cost-effective are often aspirational and do not reflect the reality of resource constraints. As a 
consequence their use is likely to reduce overall population health and exacerbate healthcare 
inequalities.  They also fail to identify the real (and greater) value of devoting more resources to 
these efforts.  By obscuring the true implications of current arrangements they do not contribute to 
greater understanding of and accountability for global and local decisions made on behalf of others 
in low and middle as well as in high income countries. We illustrate these points using examples 
from HIV/AIDS. 
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Introduction 
It is estimated that in 2010, US$6.5 trillion was spent on health across the globe.1  Somewhat 
incongruously expenditure on health is least where need is greatest  W only fifteen percent of this 
total is spent in low- and middle-income countries, where eighty five percent of people live and who 
suffer from ninety-two percent ŽĨ ƚŚĞ ǁŽƌůĚ ?Ɛ ĚŝƐĞĂƐĞ ďƵƌĚĞŶ ?1   Global health expenditure is 
estimated at $948 per person per year on average but varies enormously; from just US$12 in Eritrea 
to US$8362 in the United States.1  Many countries lack access to basic, often lifesaving, interventions 
and healthcare infrastructures are fragile - in Kenya, for instance, 43% of health facilities lack a 
minimally defined infrastructure; and in Uganda 63% of lower-ůĞǀĞů ĨĂĐŝůŝƚŝĞƐ ĚŽŶ ?ƚ ŚĂǀĞ ĚƌƵŐƐ ƚŽ
treat even basic conditions.2  This suggests that the health gains from any additional funding are 
likely to be high (i.e. high marginal productivity of health care).   
 
To address this imbalance between healthcare spending and need, efforts are made internationally 
to increase healthcare expenditures and to ŝŵƉƌŽǀĞŚĞĂůƚŚĂƚƚĂŝŶŵĞŶƚŝŶƚŚĞǁŽƌůĚ ?ƐůŽǁĞƌŝŶĐŽŵĞ
regions.  In 2012, it is estimated US$28.1 billion was spent on development assistance for health 
(DAH) from higher to lower income countries -  a large proportion going to sub-Saharan Africa and 
committed to specific disease areas such as HIV/AIDS, tuberculosis, and maternal, new-born and 
child health.3  Funding comes from a range of bilateral (i.e. country-to-country) and multilateral 
donors (e.g. World Bank, Global Fund), as well as non-governmental organizations/charities and 
philanthropic organizations.  Such efforts, in addition to significant domestically-sourced funding, 
make the financing architecture for healthcare in lower incomes very complex. 
 
A major focus for international efforts is HIV/AIDS.  It was estimated that in 2009 external financing 
accounted for 80-100 percent of total national HIV/AIDS programme spending in 12 out of 21 sub-
Saharan African countries,4 the region under the greatest burden from the disease, although 
domestic contributions to programmes are generally growing.3  In addition to funding, countries also 
look externally for guidance on the design of their HIV/AIDS programmes, in particular from the 
World Health Organisation ((WHO) which has produced and regularly updated guidelines on 
management of HIV since 2003; the latest update being new 2013 Consolidated Guidelines for 
Antiretroviral Therapy (ART)5 for use in low and middle income countries.  WHO also issues 
guidelines for the treatment and management of a number of other diseases; such as for child 
health6, malaria7, chronic non-communicable diseases8 as well as others.  
 
This picture of multi-layered financing and policy influence raises difficult questions about how HIV 
treatment as well as other healthcare interventions should be prioritized within low- and middle-
income countries.  It also poses questions regarding how much funding should be committed to 
specific disease areas, for instance to HIV as opposed to say malaria, as well as which alternative  
interventions within these disease areas ought to be implemented, and for which specific 
populations.  For example,  ?^ŚŽƵůĚresources be committed - by both domestic and international 
authorities - to HIV prevention, cotrimoxazole prophylaxis, or to HIV treatment ? ? ?  ?tŚŽƐŚŽƵůĚďĞ
eligible for interventions  W ĞǀĞƌǇďŽĚǇŽƌƐƉĞĐŝĨŝĐƉŽƉƵůĂƚŝŽŶƐ ? ? ?ĂŶĚ ?^hould priority be given to HIV 
treatment and/or prevention or instead should resources be committed to meet other healthcare 
priorities altogether, such as to malaria treatment or the management of non-communicable 
diseases? ?  
 
This paper examines these issues using examples from HIV/AIDS; although the same issues also arise 
when considering choices faced in other diseases.  It outlines how domestic governments and their 
development partners could decide to allocate resources both within and between healthcare 
programmes to generate health gains for their populations. 
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Allocating resources within HIV treatment programmes  
Given reliance on external funding and the role of international guidelines, the setting of country-
specific HIV treatment policies depends upon both domestic and international influences.  
The 2013 WHO ART Guidelines outline global norms and standards ŝŶƚĞŶĚĞĚ ƚŽ ďĞ  “ƉƌŽŐƌĞƐƐŝǀĞůǇ
ƌĞĂůŝǌĞĚ ? ďǇ ĐŽƵŶƚƌŝĞƐ ?  <ĞǇ ƌĞĐŽŵŵĞŶĚĂƚŝŽŶƐ are outlined in Table 1.  The guidelines are 
aspirational; recommending the use of new and more expensive treatments and it appears that one 
intention is to close perceived gaps in ART standards between high and lower incomes settings.  
However, large gaps in ART coverage still remain in many areas of the world.  In sub-Saharan Africa, 
only an estimated 68% of adults and 32% of children with HIV have access to ART if given according 
to the more modest 2010 guidelines; and coverage is much lower if ART is prescribed according to 
WHO 2013 guidelines where earlier initiation of ART is recommended.9  An important question is 
whether countries should commit to more ambitious approaches to ART (e.g. newer, more 
expensive ART with earlier initiation) or, firstly, to close gaps in treatment coverage for the most sick 
with current interventions. 
 
Table 1: Key new recommendations in 2013 WHO consolidated HIV treatment guidelines 
Topic 
2010 WHO guideline 
recommendations 
2013 WHO guideline 
recommendations 
Quality of evidence 
supporting 
recommendations 
When to start 
antiretroviral therapy 
 ?ч ? ? ? - Irrespective 
CD4 for TB & HBV 
CD4 ч ? ? ? Moderate  
Patient monitoring 
when on ART 
Clinical or CD4 Monitoring 
Phase in of viral load testing 
Viral load monitoring Low  
PMTCT interventions 
Option A (AZT +infant NVP) 
Option B (triple ARVs)  
Lifelong ART for all 
pregnant or breastfeeding 
women irrespective of CD4 
count (Option B Plus) 
Low  
When to start ART in 
children 
ART initiated in all children 
under two years of age - 
Irrespective CD4 
ART initiated in all children 
under five years of age - 
Irrespective CD4 
Very low  
Paediatric 1
st
 line ARVs 
(in children <3 years 
only) 
 
NNRTI based regimen 
PI based regimen - 
regardless of NNRTI 
exposure  
Moderate  
 
A notable recommendation of the 2013 WHO ART Guidelines is the use of routine viral load 
monitoring (VLM) of patients on ART, instead of currently used CD4 testing and/or clinical 
monitoring approaches.  VLM is routinely used in well-resourced settings to provide information on 
patient adherence and to guide rapid switching of ART to prevent development of resistance. 
However, in these settings patient management is individualised with good availability of many 
antiretroviral drugs for second and third-line treatment and beyond. In most lower income settings, 
only two lines of ART treatment are available, and rapid switching to much more costly secondline 
ART may not be the best approach.  Furthermore, although some observational evidence indicates 
VLM is effective at improving adherence,10 improved clinical effectiveness has not been 
substantiated in randomized control trials.11,12  It has also been suggested that VLM may reduce 
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unnecessary switching to second-line ART (when VL is undetectable)13 and could, through reduced 
viral load, lower onward transmission of HIV.14 However, VLM is also the most expensive of the 
possible monitoring approaches, with a viral load test costing $45 compared to $9 for a CD4 test and 
only the cost of a clinic visit for clinical monitoring.12 
 
To determine whether particular HIV treatment approaches, such as use of VLM, represent value for 
money within particular settings requires assessing whether expected health gains are worth the 
cost.  It is important to assess the criteria on which value-for-money (i.e. cost-effectiveness) is 
judged.   Some previous studies have indicated that VLM, despite its uncertain clinical benefit, is 
expected to be cost-effective even in sub-Saharan African settings (see Walensky et al.15 for review 
of studies as of 2010). The studies finding routine VLM to be cost-effective were assessed against 
WHO recommendations that deem an intervention offering a unit of health gain (disability adjusted 
life year (DALY) averted, a measure of survival and morbidity) at under 3 times GDP per capita in a 
country ƚŽ ďĞ  “ƌĞůĂƚŝǀĞůǇ cost-effective ? and one less than 1 times GDP per capita  “ŚŝŐŚůǇ cost-
ĞĨĨĞĐƚŝǀĞ ? ?16  However, although widely adopted, there appears to be no empirical or theoretical 
basis behind these benchmarks.17    
 
A more recent study, undertaken by the HIV Modelling Consortium to inform the 2013 WHO 
Guidelines, followed a different approach to cost-effectiveness analysis by assessing how HIV 
programme resources could be alternatively used. 12  Previous studies had indicated that ART with 
lower cost clinical monitoring delivers health gains at around US$600 per DALY-averted compared to 
no ART. 18-20  Therefore, as a result of incomplete current coverage, resources could alternatively be 
spent on ART with clinical monitoring at a cost of $600 per DALY.  The study estimated costs per 
DALY-averted associated with routine VML provision of $3,500-$6,000.12  Although within the range 
of 3 times GDP per capita for many countries this was well above the indicative $600 benchmark so 
VLM was judged very unlikely to be cost-effective in most circumstances (i.e. as additional funding 
would generate more health if used to expand current incomplete coverage rather than increase use 
of VLM). 
 
The choice of criteria to assess value for money/cost-effectiveness therefore determines which 
interventions are recommended for delivery.  Previous studies that used one approach to assess 
value for money come to the opposite conclusion to another using a different approach.  This was 
not as a result of marked differences in estimated costs and health outcomes, but solely on the basis 
of how value for money was assessed.  So the question is ?  ?thich approach should policy-makers 
use? ? 
 
Table 2 sets out a stylized example of a situation in which a country is limited in its overall resources 
and needs to decide how to spend these across ART alternatives.  Parameters are chosen to reflect a 
situation similar to that in Cameroon,  a country with an estimated ART eligible population (at 
CD4<350) of 590,00021 and purchasing power parity (PPP) GDP per capita of US$2,31222 in 2013.  We 
assume current ART coverage of 51%.9  Illustrative per patient costs and health attainment 
(measured in quality-adjusted life years (QALYs) a generic measure of health) are shown.  These 
result in a cost-per-QALY gained of $1,000 for ART with clinical/CD4 monitoring compared to no ART 
and $3,000 for ART with VLM compared to ART with clinical/CD4 monitoring. 
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Table 2: Stylized current state of ART provision in Cameroon with clinical/CD4 monitoring 
 
Illustrative 
per 
patient 
total costs 
Illustrative 
per patient 
total health 
attainment 
(QALYs) 
Incremental 
cost-
effectiveness 
ratio (ICER) 
ART 
coverage 
Health 
attainment 
(QALYs) 
Illustrative 
total costs 
No treatment $2000 5 - 49% 1.45m $602m 
ART with clinical/CD4 
monitoring 
$22000 25 
$1000 per 
QALY 
51% 7.52m $6,620m 
ART with VL 
monitoring 
$28000 27 
$3000 per 
QALY 
0% 0 $0 
    Total 8.97m $7,722m 
Note: Approx. ART eligible (CD4<350) adult population of Cameroon, 2012, is 590,000.
9
  
 
We assume that additional resources are committed to the ART programme (either by Government 
or donor partners) which increase the available budget by 25% over the evaluated period.  This can 
either be used to provide (i) VLM to all those currently receiving ART with clinical/CD4 monitoring 
(Table 3a); or (ii) ART based upon clinical/CD4 monitoring for those not currently receiving ART 
(Table 3b).  The former VLM approach is estimated to lead to overall population health gain of 
0.6million QALYs; this would be deemed cost-effective according to the WHO recommended 
benchmark of 3 times GDP per capita.  However, expanding HIV testing and ART availability to those 
in need would increase population health by 1.8million QALYs (3 times the amount; the ratio of 
ICERs).  Moreover, it would lead to more equal population health outcomes with a 16% increase in 
ART coverage. 
 
This example is characteristic of many real policy decisions.  Applied cost-effectiveness analyses in 
HIV/AIDS23,24 and other disease areas25,26 routinely make recommendations on the basis of WHO 
cost-effectiveness thresholds, aiming to promote access to new and more expensive therapies.  
However, whenever there are gaps in coverage of current interventions, as is typically the case in 
low- and middle-income countries, due to finite resources, the promotion of new and more 
expensive therapies risks lowering overall population health attainment and increasing health 
inequalities.  Economic theory would highlight that the only justifiable way to inform priorities is to 
adopt an approach that carefully considers how else resources can be used to improve health.27 
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Table 3: Alternative ways of spending ART programme resources  
(a) Invest in viral load monitoring 
 
Illustrative 
per patient 
total costs 
Illustrative 
per patient 
total health 
attainment 
(QALYs) 
Incremental 
cost-
effectiveness 
ratio (ICER) 
ART 
coverage 
Health 
attainment 
(QALYs) 
Illustrative 
total costs 
No treatment $2,000  5 - 49%  1.45m   $602m  
ART with 
clinical/CD4 
monitoring 
$22,000  25 
$1000 per 
QALY 
0%  -     -    
ART with VL 
monitoring 
$28,000  27 
$3000 per 
QALY 
51%  8.12m   $8,425m  
    Total 9.57m $9,027m 
(b) Invest in ART scale-up      
 
Illustrative 
per patient 
total costs 
Illustrative 
per patient 
total health 
attainment 
(QALYs) 
Incremental 
cost-
effectiveness 
ratio (ICER) 
ART 
coverage 
Health 
attainment 
(QALYs) 
Illustrative 
total costs 
No treatment $2,000  5 - 34%  0.99m   $395m  
ART with 
clinical/CD4 
monitoring 
$22,000  25 
$1000 per 
QALY 
67%  9.81m   $8,632m  
ART with VL 
monitoring 
$28,000  27 
$3000 per 
QALY 
0%  -    - 
    Total 10.80 $9,027m 
Note: Approx. ART eligible (CD4<350) adult population of Cameroon, 2012, is 590,000.
9
  
 
Allocating resources between HIV Treatment and other healthcare programmes 
Many working in specific disease areas will consider the comparison just presented unfair.  They may 
ĂƐŬ ?  ?tŚǇ ĐĂŶ ?ƚ ƌĞƐŽƵƌĐĞƐ be committed to both VLM and ART scale-ƵƉ ? ?  The 2013 WHO ART 
Guidelines are aspirational and were perhaps developed in the hope that once policies are set, 
resources will follow.  dŚĞƉƌŽďůĞŵŝƐƚŚĂƚƚŚŝƐ ?ĂƐƉŝƌĂƚŝŽŶĂůĂƉƉƌŽĂĐŚ ?ĚŽĞƐŶŽƚĂĚĚƌĞƐƐƚŚĞƋƵĞstion 
of how best to use existing resources to have the greatest impact on health outcomes.  In fact, 
failing to properly take account of existing constraints on resources can lead to decision that make 
matters worse if resources are reallocated from more effective programmes and interventions, 
possibly in other disease areas, in an attempt to achieve these aspirations.   It also obscures the 
implications of the reality of existing constraints and does not highlight the potential health effects 
of increasing the resources available.  Moreover, HIV/AIDS is not the only disease area with worthy 
claims on such healthcare resources, although some budget allocations may have to be spent on HIV 
as a result of funder specifications.  It is appropriate then to question whether resources spent on 
HIV treatment policies (e.g. by following the WHO Guidelines) would generate more or less health 
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than spending on other healthcare needs.  The WHO cost-effectiveness benchmarks in no way 
reflect this assessment. 
 
As highlighted previously, interventions in many disease areas are not fully provided and could 
generate health gains at comparatively low cost.  Childhood interventions, particularly vaccinations, 
often provide greatest value yet remain underprovided - rotavirus vaccination, for instance, has 
been associated with a cost-per-DALY-averted of $43;28 and treatment of severe malnutrition costs 
$53 per DALY-averted.29  Even within HIV, prevention of mother-to-child HIV transmission costs 
below $150 per DALY-averted using available intervention;30 yet a coverage gap of 38% remains 
across low- and middle-income countries.9 The lack of basic health care implies that if extra 
resources are available there are areas where very large health gains could be achieved for minimal 
spending.  
 
Is there a way out of the straightjacket of resource constraints? 
dŚĞĂƉƉƌŽĂĐŚŽĨ ?ĂƐƉŝƌĂƚŝŽŶĨŝƌƐƚ ?tends to rally civil society, patient advocacy groups and healthcare 
practitioners  W providing interventions that are deemed amongst the best available seems a worthy 
cause.  However, when resources are committed to areas other than where they will generate 
greatest gains this results in real losses in health for individuals and society as a whole. 
 
The use of WHO recommended cost-effectiveness benchmarks of 1 and 3 times GDP per capita has 
no theoretical or empirical basis. Analyses using these benchmarks have the tendency to make 
ĂůŵŽƐƚĂůůŚĞĂůƚŚĐĂƌĞŝŶƚĞƌǀĞŶƚŝŽŶƐŶŽƚŝŽŶĂůůǇ ?ĐŽƐƚ-ĞĨĨĞĐƚŝǀĞ ?ĞǀĞŶŝŶƚŚĞŵŽƐƚƌĞƐŽƵƌĐĞĐŽŶƐƚƌĂŝŶĞĚ
countries.  Perhaps they were designed for this intent?  However, they stand in stark contrast to 
disturbing levels of unmet need within low- and middle-income countries and, in all likelihood, 
exacerbate this situation.  They take no account of whether resources could be better used 
elsewhere. 
 
As means of comparison, the most comprehensive assessment of health forgone through resources 
being committed to particular interventions is from the UK.31  This estimates a benchmark of 0.52 
GDP per capita in that country.  Lower income countries commit a lower proportion of their GDP to 
prepaid pooled healthcare funding than higher income countries like the UK32 and it has been 
suggested the relationship between healthcare spending and health attainment across countries is 
subject to diminishing returns.1,33  Thus a reasonable conclusion would be that a suitable benchmark 
for lower income countries is unlikely to be higher than 0.52 GDP p.c. and may well be considerably 
lower. 
 
It may be claimed that any resources committed to particular interventions from outside of a 
country are additional to those otherwise available and so do not impose opportunity costs on the 
country ?Ɛ limited budgets.  However, external funds could also be used for other purposes  W even if 
in other jurisdictions.  It should be hoped that external funders commit resources to where they will 
generate greatest gains; given high need and constrained financing, this will generally be in the 
lowest income settings.  The way in which external resource commitments are made requires 
scrutiny in this respect.  
 
It may also be queried whether the overall level of resources committed to healthcare is appropriate 
in a country.  This requires assessing whether more or fewer resources should be devoted to health 
relative to other economic activities and societal concerns.  Although this is ultimately a political 
question, it can be informed by examining local public preferences for forgoing non-health forms of 
consumption to achieve improved population health.  It is certainly not the role of the WHO to state 
how much should be spent on healthcare within jurisdictions.  Furthermore, it is highly unlikely this 
should be at a level of 1-3 times GDP per capita, which implies spending more per person-year on 
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health than the total per person economic output.  Even if health should be funded to this level, 
there would be no justification for not spending first on interventions offering greatest health gains. 
There appears no way out of the straightjacket of resource constraints; yet this is no reason for 
despair.   Recognizing constraints and acting within them is the route to providing greatest health 
benefits to the population from the means available.   It is only by being explicit about the reality of 
the implications of the resources currently available that the value of devoting more resources to 
these efforts can properly be highlighted.  In this sense, economic analysis founded on an evidence 
based approach to judging cost-effectiveness in low and middle income countries can also 
contribute to holding global and local decision makers, as well as wider society, to account (and 
enable informed reflection) on the adequacy  and the justice of current arrangements. 
  
Key Messages 
x Efficient allocation of limited resources requires using these resources where they can generate 
greatest benefits. 
x This requires policymakers to carefully assess which interventions provide greatest health gains 
from limited resources available and not to fund interventions which for go more health benefits 
than they generate. 
x Widely employed resource allocation norms recommended by the World Health Organization 
(WHO; i.e. cost-effectiveness thresholds based upon gross domestic product (GDP) per capita) 
conflict with the central principles of resource allocation.  Their continued use risks reducing 
population health and exacerbating health inequalities in some of the poorest countries in the 
world.   
x Judging cost-effectiveness instead based upon the reality of resource constraints would facilitate 
understanding of the value of committing more resources to healthcare.  It would also 
contribute to holding global and local decision-makers, and society more generally, to account 
by enabling informed reflection on the adequacy and justice of current arrangements. 
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